|
| 37526080 | Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. | J Clin Invest | 2023 |
| 37747363 | Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. | | 2023 |
| 37662390 | Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. | | 2023 |
| 37790523 | Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. | | 2023 |
| 36581339 | Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant. | | 2023 |
| 36511813 | Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. | Blood Cancer Discov | 2023 |
| 36804376 | Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience. | | 2023 |
| 36861411 | <i>PARP1</i> and <i>POLD2</i> as prognostic biomarkers for multiple myeloma in autologous stem cell transplant. | Haematologica | 2023 |
| 34817872 | A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. | American Journal of Hematology | 2022 |
| 35927247 | Venetoclax ex vivo functional profiling predicts improved progression-free survival. | Blood Cancer J | 2022 |
| 36114265 | Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. | Leukemia | 2022 |
| 34626863 | Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. | Transplantation and Cellular Therapy | 2022 |
| 35259002 | Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. | Journal of Clinical Oncology | 2022 |
| 34969749 | A Single Nucleotide Polymorphism (SNP) in the Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy. | Anticancer Research | 2022 |
| 35122287 | Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. | Pharmacotherapy | 2022 |
| 34539628 | Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. | Frontiers in Immunology | 2021 |
| 32296125 | Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. | Leukemia | 2021 |
| 33492438 | A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. | Cancer Chemotherapy and Pharmacology | 2021 |
| 33738338 | Oncolytic herpes simplex virus infects myeloma cells <i>in vitro</i> and <i>in vivo</i>. | Mol Ther Oncolytics | 2021 |
| 33731366 | Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. | Clin Cancer Res | 2021 |
| 33649772 | Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. | Blood | 2021 |
| 33275813 | Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. | Am J Hematol | 2021 |
| 34618345 | Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. | European Journal of Drug Metabolism and Pharmacokinetics | 2021 |
| 34667843 | Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. | Laryngoscope Investig Otolaryngol | 2021 |
| 34778800 | Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. | Blood Cancer Discov | 2021 |
| 31518644 | Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. | Biology of Blood and Marrow Transplantation | 2020 |
| 32024950 | Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). | Leukemia | 2020 |
| 32298201 | Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. | J Clin Oncol | 2020 |
| 32285957 | Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant. | British Journal of Clinical Pharmacology | 2020 |
| 32094461 | Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. | Leukemia | 2020 |
| 32988896 | Association of <i>ANRIL</i> Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. | Anticancer Res | 2020 |
| 30716453 | BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. | Biology of Blood and Marrow Transplantation | 2019 |
| 31767829 | Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. | Blood Cancer J | 2019 |
| 35005626 | Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT). | | 2019 |
| 29983352 | Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. | Journal of Geriatric Oncology | 2019 |
| 30591441 | A Single Nucleotide Polymorphism in Was Associated With Clinical Response in Multiple Myeloma Patients. | Anticancer Research | 2019 |
| 30332496 | Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. | Cancer | 2019 |
| 30413812 | Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease? | Bone Marrow Transplantation | 2019 |
| 30277092 | Most multiple myeloma patients have low testosterone. | Leukemia and Lymphoma | 2019 |
| 31470355 | Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization. | Leukemia Research | 2019 |
| 31171418 | Registering a CD38 antibody upfront for multiple myeloma. | Lancet, The | 2019 |
| 31013254 | Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. | JCI Insight | 2019 |
| 30951198 | Daratumumab in multiple myeloma. | Cancer | 2019 |
| 30672004 | Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. | British Journal of Clinical Pharmacology | 2019 |
| 30943323 | Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. | European Journal of Haematology | 2019 |
| 30718797 | BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. | Bone Marrow Transplantation | 2019 |
| 29679038 | Ninety-minute daratumumab infusion is safe in multiple myeloma. | Leukemia | 2018 |
| 30218008 | Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. | Leukemia | 2018 |
| 30343510 | Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant. | CPT Pharmacometrics Syst Pharmacol | 2018 |
| 30288349 | Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. | OncoImmunology | 2018 |